The Future of Cancer Therapy
Innovative science, breakthrough technology, first-in-class treatments
Pipeline
RGX-104
RGX-104 is a novel oral small molecule immunotherapy in development for the treatment of solid tumors, including drug-resistant malignancies.
Pipeline
RGX-202
RGX-202 is an oral small molecule cancer metabolism inhibitor in development for the treatment of gastrointestinal cancers, including colorectal and gastric cancer.
Pipeline
RGX-019
RGX-019 is a monoclonal antibody that targets a key pathway that drives tumor progression and metastasis of several cancer types, including triple-negative breast cancer.
Patients
Clinical Trials
We are actively recruiting patients for phase 1 first-in-human, dose escalation and expansion studies of RGX-104 and RGX-202.
Our Science
Science underlying Rgenix’s technology and pipeline has been published in leading scientific journals.
News
-
Rgenix Names Industry Veteran to Chief Medical Officer Role
Robert Wasserman, MD, joins Rgenix with more than 20 years of oncology clinical development experience and prior senior roles
-
Rgenix Presents Pre-Clinical Data on RGX-019 at the 2019 AACR Annual Meeting
Pre-clinical data demonstrates first-in-class MERTK selective inhibitor with novel mechanism of action Rgenix has initiated IND-enabling studies of RGX-019 FOR IMMEDIATE
-
Rgenix To Present Abstract on RGX-019 at the 2019 AACR Annual Meeting
New York, NY – April 1, 2019- Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and